Uterotonic Plants and their Bioactive Constituents

Abstract

Abnormalities in the process of uterine muscle contractility during pregnancy and birth can have major clinical implications, including preterm labour, which is the single largest cause of maternal and prenatal mortality in the Western world and a major contributor to childhood developmental problems. In contrast, induction of labour may be necessary in certain conditions. Currently used interventional therapies to suppress (tocolytic agents) or to induce (uterotonic agents) uterine contractions lack potency and/or selectivity and can have harmful side effects for mother and baby. Nature’s diversity has always been, and still is, one of the biggest resources of therapeutic lead compounds. Many natural products exhibit biological activity against unrelated targets, thus providing researchers with starting points for drug development. In this review we will provide an overview of uterine muscle physiology, describe currently available biological screening procedures for testing of uterotonic plant compounds and will summarise traditionally-used uterotonic plants, their active components and their mechanisms, primarily focusing on uterotonic active circular plant peptides called cyclotides. Finally we will comment on the discovery of novel cyclotide-producing plant species and the possibility for the development of novel plant-derived uterotonic and tocolytic drugs.

Abbreviations

AC: adenylyl cyclase
CCK: cyclic cystine knot
COX-2: cyclooxygenase-2
CRH: corticotropin-releasing hormone
GPCR: G-protein coupled receptor
IL: interleukin
IP3: D-myoinositol 1,4,5-triphosphate
MLC: myosin light chain
NF: nuclear factor
OT: oxytocin
PL: phospholipase
R: receptor
SFE: supercritical fluid extraction
SR: sarcoplasmic reticulum
TNF: tumour necrosis factor

Introduction

Traditional medicine relies on the use of certain herbal plants and other remedies for beneficial effects during pregnancy, to induce labour, in the removal of retained placenta and management of post-partum bleeding. However, some of these medicines have harmful side effects and when taken in large quantities can lead to the death of the unborn baby and/or uterine rupture, and other longer term effects on the mother or baby. Most often the biological effects elicited by these remedies are due to biomolecules (small chemicals, peptides or proteins) that primarily act on the uterus. The nature of these actions may involve the modulation of uterine contractions at labour, resulting in either the stimulation (“uterotonic”) or inhibition (“tocolyic”) of myometrial muscle contractions. In this review we will provide an overview of uterine muscle physiology, describe currently available biological screening procedures for testing of uterotonic plant compounds and will summarise traditionally-used uterotonic plants, their active components and their mechanisms, primarily focusing on uterotonic active circular plant peptides called cyclotides. Finally we will comment on the discovery of novel cyclotide-producing plant species and the possibility for the development of novel plant-derived uterotonic and tocolytic drugs.
from the Rubiaceae and Violaceae families, which have shown to be uterotonic agents. We will begin this article with a thorough description of uterine physiology and molecular details of uterine smooth muscle contractility.

Uterine muscle physiology

Biology of the uterus

The uterus is the central organ of reproduction. It is a thick, pear-shaped, muscular organ approximately 7 cm long, and 4–5 cm wide at its widest point. It is divided functionally and morphologically into three sections, namely the cervix, the isthmus and the main body of the uterus (corpus uteri) [1]. The myometrium is the middle muscular layer that makes up the major proportion of the uterine body. Myometrial smooth muscle is arranged in undefined layers and contractile forces can occur in any direction enabling the uterus to assume virtually any shape. Through growth and stretch during pregnancy, the myometrium provides the protective environment for the developing foetus. Then with the onset of labour it contracts rhythmically to expel the foetus and placenta. Smooth muscle fibres are composed of spindle-shaped cells, each with one centrally located nucleus. Typically, they have a diameter of 2–10 µm and a length of several hundred µm [2]. Smooth muscle cells are embedded in an extracellular matrix composed principally of collagen fibres, which facilitate the transmission of contractile forces generated by individual cells. They are organised into sheets of closely opposed fibres, oriented at right angles to each other. These sheets form two distinct layers, the “longitudinal layer”, which consists of a network of bundles of smooth muscle cells generally oriented in the long axis of the organ, and the “circular layer”, in which the fibres are arranged concentrically around the longitudinal axis of the organ [3]. Contraction of the longitudinal layer causes the organ to dilate and shorten, whereas contraction of the circular layer causes the organ to elongate; thus alternating contraction and relaxation of these layers enables the uterus to expel its contents at birth [2].

Uterine muscle contractility

The onset of labour is facilitated by phasic myometrial contractions that are driven by the development of action potentials across the plasma membrane, resulting from a transient increase in the cytosolic free Ca²⁺ concentration [4]. In this case (calcium-dependent smooth muscle contraction), calcium is released from the sarcoplasmic reticulum (SR) and from extracellular stores through voltage-gated calcium channels. Therefore smooth muscle contractility by different agonists or by electrical depolarisation results in a rapid increase in [Ca²⁺]i [5]. Ca²⁺ binds to four binding sites of calmodulin causing a conformational change allowing the calmodulin–calcium complex to interact with inactive myosin light chain kinase (MLCK), thus activating its enzymatic properties [6]. MLCK rapidly phosphorylates the 20 kDa myosin light chain (MLC). Phosphorylation of MLC leads to conformational changes in the myosin head that causes actin activation of myosin ATPase, resulting in force generation and/or shortening (contraction) of the muscle fibres [7]. Dephosphorylation of MLC by MLC phosphatase (MLCP) results in smooth muscle relaxation [8]. Myometrial contraction is influenced by a variety of physiological mechanisms involving intracellular signalling, calcium, ion channels, cell membrane receptors, peptides, metabolic and neuronal factors and hormones [9]. The most important factors are described below and are summarised in Fig. 1.

G-proteins and G-protein coupled receptors involved in myometrial contraction

G-protein coupled receptor (GPCR) activation can result in profound stimulatory or inhibitory effects on myometrial contraction. For example, receptors coupled to Gaα, e.g., oxytocin (OT) receptors, endothelin receptors, prostaglandin (PG) receptors E (subtype EP₁), F (FP) and thromboxane A₂ receptor, stimulate contractility by activating the phospholipase C (PLC)–Ca²⁺ pathway; receptors coupled to Gaα, e.g., β₂-adrenoceptors as well as PG receptors DP, EP₂ and IP relax the uterus by stimulating adenyl cyclase (AC) and increase myometrial cAMP levels; while
receptors coupled to Gα, e.g., α2-adrenoceptors, muscarinic receptors, potentiate contractility by inhibiting cAMP production [10]. Activated G-protein subunits trigger many effectors, which can then regulate ion channel activity [11] – directly or indirectly, by stimulating/inhibiting phosphorylation pathways, initiating intracellular cascades leading to elevation of cytosolic Ca2+ or cAMP, or by generating various lipid-derived compounds that can alter channel activity [12]. Kᵢ, KATP and Maxi-K channels are all potential targets for direct regulation by GPCRs or the second messengers generated by GPCR-linked pathways [9, 10, 12]. In the following paragraphs we will provide more detail on the myometrial effects of OT, PGs and corticotrophin releasing hormone (CRH).

**Oxytocin:** OT is a potent uterotonic nonapeptide hormone [13], which is known to act both directly and indirectly to stimulate uterine smooth muscle contraction and is widely used for the artificial induction of labour [14]. It circulates as a free peptide in the bloodstream and, as with all hypothalamic hormones, is released discontinuously in a pulsatile fashion [15]. Its release into the bloodstream can be stimulated by the administration of PGs [16] or dopamine [17]. OT mediates most of its effects through the OT receptor (OTR), which is a member of the OT/vasopressin GPCR family [18] of the Gαᵢ subfamily, to stimulate PLC activity [19]. OT induces contraction by elevating intracellular calcium concentration ([Ca²⁺]ᵢ), first by PLC-mediated d-myoinositol 1,4,5-triphosphate (IP₃) induced release of Ca²⁺ from internal stores [20–22], followed by influx of extracellular Ca²⁺ via voltage- and receptor-operated calcium channels [20, 23] or capacitative calcium entry [24]. OT also stimulates an increase in cytoplasmic phospholipase A₂ (PLA₂) activity and induces cyclooxygenase-2 (COX-2), the two major enzymes of PG biosynthesis [25]. OTR mRNA expression is influenced by several factors, including hormones, certain cytokines and transcription factors [18].

**Prostaglandins:** PGs are members of the eicosanoid family of proteins. They are lipid mediators produced by the uterus, foetal membranes and the placenta and are capable of modulating uterine contractions [26] and have been used in pregnancy for a variety of treatments [27]. When PG receptors are bound by their specific ligand, distinct intracellular pathways are activated, linked to the contractile (EP₁, EP₃, FP, thromboxane) or the relaxant (EP₂, EP₄, IP, DP) receptor isoforms [28]. PGE₂ and PGF₂α play important roles in myometrial contraction, cervical ripening and the initiation of parturition in humans [29]. The contractile effect of PGs is based on their ability to mobilise calcium and inhibit AC activity. PGE₁ and PGF₂α stimulate Ca²⁺ release from the SR of the myometrial cells [30]. PGs exert their effects through a number of GPCRs [31]. Binding of PGF₂α to its contractile receptor stimulates G-protein (Gαᵢ₁₁) activation of PLC and PLA₂, which stimulate production of IP₃ and intracellular calcium release [32, 33]. The released IP₃ mobilises [Ca²⁺]ᵢ from the SR, resulting in increased uterine contractility. PGE₂ exerts a dose-dependent increase in [Ca²⁺]ᵢ mediated through Gαᵢ₅ [34]. The effects of PGE₂ and PGF₂α are mediated mainly through EP and FP receptor subtypes, respectively [35]. PGs have both direct and indirect effects on myometrial contractions, further increase uterine sensitivity to uterotropic agents, synchronise myometrial contractions [36, 37] and alter hormone synthesis [38]. Additionally, PG receptors EP₂ and EP₄ are responsible for smooth muscle relaxation and uterine quiescence [28].

**Corticotropin-releasing hormone:** CRH is a 41 amino acid polypeptide which mainly functions as the hypothalamic regulator of the mammalian stress response. CRH stimulates adrenocorticotropic hormone release from the anterior pituitary gland and consequently cortisol secretion from the foetal adrenal gland [39]. CRH action is mediated by multiple receptor subtypes with differential patterns of expression depending on the state of the myometrium (non-pregnant or pregnant – term/preterm) [40]. During most of pregnancy CRH, acting via CRH receptor subtypes coupled to AC, plays a “protective” role by promoting myometrial quiescence via generation of cAMP and cGMP, and upregulation of nitric oxide synthase expression [41]. CRH may also prevent contractions by inhibiting production of PGE₂ [42]. During the third trimester, CRH derived from the placenta is secreted into the maternal circulation in large amounts [40]. At term, myometrial contractility is enhanced by a complex series of molecular switches, involving the upregulation of OTR expression and cross-talk between the OT and CRH receptors [43]. OT action is mediated via pertussis toxin-sensitive G proteins, which directly inhibit AC and via activation of protein kinase C, phosphorylate specific CRH receptor subtypes, leading to desensitisation [42]. Thus, CRH receptor binding affinity for CRH is lowered, causing a reduction in intracellular CAMP levels, which results in a shift in the intracellular microenvironment in favour of contractility [41]. The function of CRH at term now changes, as it is able to enhance the contractile response of the myometrium, via distinct lower-affinity CRH receptor subtypes, through stimulation of prostaglandin PGF₂α and PGE₂ production [44]. CRH also stimulates placental release of OT [39]. Another function of CRH at term is the stimulation of cortisol and the production of dehydro-epi-androstenedione, the precursor to oestradiol from the foetal adrenal gland [45].

**Steroid hormones involved in myometrial contraction**

**Oestrogens:** Oestrogens comprise a group of steroid hormones, including oestradiol, oestriol and oestrone. They are synthesised mainly in the ovaries, although small amounts are also produced in the adrenal cortex and the placenta. During pregnancy oestrogens are responsible for uterine growth which ceases at the end of pregnancy, the consequent increasing stretch of the uterine wall stimulates contraction [46]. In human nonpregnant myometrium, the inhibitory action of oestrogens is achieved through inhibition of receptor-operated calcium channels and possibly also the release of intracellular calcium [47]. Oestrogen is also linked to an increase in PLC isozyme expression in uterine smooth muscle [48] and has been shown to up-regulate OTR concentration in myometrial cells [49]. Most, if not all, of the actions of oestrogens are mediated by interaction with the specific nuclear receptors, ERα and ERβ [50, 51].

**Progesterone:** Progesterone is another steroid hormone, primarily produced by the corpus luteum of the ovary, but also by the placenta that prepares the lining of the uterus for implantation of a fertilised ovum and maintains this state during pregnancy [52]. It is a pro-pregnancy hormone and negatively regulates many of the labour associated proteins. It supports uterine quiescence by stimulating a variety of relaxant mechanisms, such as the nitric oxide system, by suppressing myometrial responsiveness to uterotonic agents, primarily by inhibiting gap junctions [53]. It functionally opposes oestrogen action. In humans a functional withdrawal of progesterone precedes labour onset, the switch from the growth phase of pregnancy to the uterine stretch observed at the end of pregnancy due to pressure on the uterine wall from the foetus appears to be regulated by progesterone. Progesterone withdrawal increases the attachment of myocytes...
to the intercellular matrix through integrins, and this process leads to the activation of mitogen-associated protein kinase and increases contractility [46]. Progesterone mediates its effects through its receptors, members of the nuclear receptor subfamily PR-A, PR-B and PR-C isoforms [54].

Inflammatory signals in labour and myometrial contraction

Many of the biochemical events involved in parturition resemble an inflammatory reaction, with growing evidence pointing to a crucial role for pro-inflammatory cytokines and PGs in labour [55]. This may in part be due to increased surfactant protein production in the foetal lung. Firstly, cortisol production in the foetal adrenal glands increases due to increased placental CRH production [56]. This results in foetal lung maturation with an increase in surfactant proteins which are critical for lung function. The surfactant proteins enter the amniotic fluid where they have macrophage activating properties [46,57]. In the mouse, surfactant protein A activates amniotic fluid macrophages, and these cells play an active role in labour onset [58]. In humans it is postulated that the surfactant proteins may stimulate the inflammation observed in the foetal membranes, cervix and myometrium at the time of labour [46]. Parturition is characterised by an influx of inflammatory cells into the maternal tissues, placenta and foetal membranes [59,60] and increased expression of pro-inflammatory cytokines in both preterm and term labour. Elevated levels of interleukin (IL)-1β, IL-6 and tumour necrosis factor TNFα are detected in amniotic fluid [61,62], myometrium and choriodecidua [59,63] and cervicovaginal secretions [64]. These pro-inflammatory cytokines are thought to contribute to labour onset by stimulating the production of IL-8 and PGs. IL-8 acts in the formation of the lower uterine segment in late pregnancy and in mediating the inflammatory infiltrate seen in myometrium during labour [55]. IL-8 expression is induced by IL-1β, TNFα, lipopolysaccharide and phorbol esters. It has promoter binding sites for nuclear factor NF-κB, AP-1 and C/EBP [65]. PGs, in turn, cause cervical ripening and foetal membrane remodelling [66]. Both term and preterm labour are also associated with NF-κB activation [58], which, in turn, increases expression of genes promoting myometrial contractility, including the PGF2α receptor [66], the gap junction protein connexin 43 [67], the OTR [68] and COX-2 [69]. Following the description of myometrial signalling and uterine contractility pathways, we will provide an overview of uterotonic test systems.

Collagen contractility assay

Collagen is an ideal substrate for uterotonic assays as it forms the main component of the extracellular matrix in vivo and it does not cause cytotoxicity. Bell et al. described the formation of a “tissue-like structure” produced by seeding fibroblasts in a collagen matrix and collagen lattices are now widely used as in vitro models for many diverse purposes [78]. Furthermore, preparation of lattices can be altered to best mimic the tissue of interest. Using an isolated cell system allows the study of effects on cells by individual stimuli, without interference from other sources. Type 1 collagen is widely available, so studies are not restricted by sample number. With tissue strip experiments, inherent differences exist between myometrial samples; however, with this collagen contractility system a uniform solution of cells and collagen is used, ensuring that all replicates are comparable. Examples of the utilisation of the collagen contractility assay on uterine cells include: (i) the monitoring of the effects of endothelin-1 on human myometrially-derived smooth muscle cells [79], (ii) determination of the effect of OT and its inhibitors on two human myometrial cell lines, i.e., telomerase-immortalised human myometrial cells (hTERT-C3) and a cell line derived from primary culture...
of human myometrial cells [80], (iii) study on primary human uterine smooth muscle cells (hUtSMCs) that demonstrated increases in gel contraction with OT, KCL and TNFα [81] and (iv) the modulation of primary hUtSMC and hTERT-HM myometrial smooth muscle cell contractility by thrombin, the ROCK inhibitor Y-27632, TNFα and the prostaglandin inhibitor indomethacin [82–84]. Therefore, the collagen contractility assay is an effective and robust in vitro model of human myometrium [79,80,82–84] (Fig. 2).

In particular, the assay allows the determination of the biological effects of various unknown (plant) compounds on uterine smooth muscle contractility. To determine the biochemical pathways involved in the modulation of myometrial contractility some clinically used inhibitors may be applied to the assay, such as indomethacin (a non-selective PG receptor inhibitor), COX-2 inhibitors, atosiban (OTR inhibitor), nifedipine (calcium channel blocker), ritodrine and terbutaline (β2-adrenergic receptor agonists), salbutamol (β2-sympathomimetics) and Y-27632 (Rho kinase inhibitor). Furthermore, this contractility assay set-up allows investigations at the molecular biology level by isolating RNA and protein from the cells in the collagen matrix, which has been previously demonstrated [82]. RT-PCR and Western blotting techniques may be utilised to monitor gene and protein expression changes.

Having presented a thorough description of uterine physiology, the molecular mechanisms of myometrial muscle contractility and currently available uterine contractility assay systems, we will now provide an overview of traditionally-used and recently identified uterotonic plants and their bioactive constituents.

Uterotonic Plants and their Bioactive Constituents

The use of herbal medicine to alleviate problems associated with gynaecological conditions of menstruation and menopause, to support health during pregnancy and to facilitate childbirth is common amongst many traditional cultures. Detailed ethnobotanical surveys have been reported for several native communities around the world and many traditionally-used plants or remedies have been identified.

Traditionally used plants in gynaecology

Traditional cultures rely on the beneficial effects of herbal remedies during pregnancy, birth and post-partum care. The knowledge and the correct use of these natural medicines has been acquired and improved over many generations. Documentation of traditional knowledge of medicinal plants is crucial, since it provides chemists and pharmacologists with starting points for “targeted” analysis, discovery of novel remedies and natural drugs for the treatment of pregnancy and birth-related problems.

Ethnobotanical studies with the aim to identify and document the native use of plants to treat gynaecological health issues have been reported, e.g., for Argentina [85], China [86,87], Dominican Republic [88], Honduras [89], Indonesia [90], Laos [91], Mexico [92], Tonga [93], Vanuatu [94], Thailand [95] and many others. Some studies provide initial pharmacological characterisation, e.g., preliminary biological testing of uterotoxic effects of 28 plants from Ethiopia [96], identification of active compounds of 12 plant species from Guatemala that bind to oestrogen and/or serotonin receptors [97] and identification of at least five uterotonic plant species from South Africa (see below) [98].

The use of plant remedies is also documented in native Northern America, where herbal medicines are taken as tonics during pregnancy to prepare for labour (e.g., raspberry leaf, partridge berry and stinging nettle), to prevent miscarriage (e.g., black cohosh and false unicorn) and to induce labour (blue cohosh, black cohosh and beth root) [99]. Preparations of black cohosh root (Actaea racemosa [Nutt.] L.) and Goldenseal root (Hydrastis canadensis L.) and Chaste tree fruits (Vitex agnus-castus L.) are listed in the U.S. Pharmacopoeia and are available as dietary supplements to be used for premenstrual stress syndrome, as emmenagogue agents and for gynaecological problems. Other traditionally used medicines, such as raspberry leaves (Rubus idaeus L.) [100], castor oil (Ricinus communis L.) [101] and cotton bark root (Gossypium hirsutum L.) [102] are again receiving attention from midwives for applications during pregnancy and labour [103,104].

Infusions of various plant species have been used from early times to treat ailments of pregnant women in traditional medicine of central European countries, e.g., Austrian traditional medicine [105] as well as in some countries of the Balkans, e.g., Bosnian traditional medicine [106]. For example, German chamomile (Matricaria recutita L.), small-leaved lime (Tilia cordata Mill.), and large-leaved lime (Tilia platyphyllos Scop.) as well as aerial parts of marjoram (Origanum majorana L.) and fruits of caraway (Carum carvi L.) have been used to ease the birthing process.
Uterotonic active plants

There is a vast array of information available on traditionally used herbs to treat gynaecological problems. The medicinal properties of many of these plants have not yet been studied in molecular detail but it is clear that they may affect a number of different physiological targets and pathways in the female body. The focus of this review is on uterotonic plants and we will briefly provide the selection criteria of plants listed and described in this article. There are at least four categories of medicinal plants (and their active constituents) that exhibit activity on the uterus:

1. Symptomatic/traditional categorisation: Plants used for the treatment of menstruation problems – dysmenorrhoea (= severe uterus pain during menstruation) or menopause symptoms, herbal medicines with oxytocic or emmenagogue properties (= herbs that stimulate blood flow in the pelvic area and uterus) used during childbirth and pregnancy and herbal medicines with abortive properties.

2. Biological categorisation: Uterine-stimulating plants (uterotonic) and uterine-inhibiting plants (tocolytic).

3. Pharmacological categorisation: Agonists or antagonists (full, partial, inverse) of uterine contractility-related pathways.

4. Chemical categorisation: Small chemical compounds, peptides or proteins.

We have included plants, plant extracts or pure plant-derived compounds that have demonstrated the stimulation of uterine contractility (uterotonic) in vivo or in vitro. Plants that indirectly elicit effects on the uterus, such as the increased production of uterotonic substances (e.g., observed upon the administration of *Artemisia monosperma* in rats [107]) or the upregulation of PG synthesis, have specifically not been included. We have also not included substances that inhibit uterine contractility (tocolytic agents). Furthermore, any pure plant-derived uterotonic compounds that are already marketed drugs (or in clinical trials) as stimulants of uterine contractility, have not been included. Following these criteria, we have surveyed the literature for uterotonic plants and active plant compounds, which are listed in Table 1.

Uterotonic plant compounds: the discovery and application of cyclotides

Upon compilation of the comprehensive list of uterotonic plants, we will describe uterotonic plant constituents, with an emphasis on the characteristics of the active compounds and their molecular mechanisms. Of particular interest is a class of circular plant peptides, so-called cyclotides, which have recently attracted much attention due to their pharmaceutical and agro-chemical applications.

We have identified and summarised (Table 1) at least 40 plant species, which appear to have pharmacological evidence for uterotonic activity. It is clear that there are many more uterotonic plants to be discovered, but they have either not yet been tested or do not appear as “uterotonic” in the literature. Although the majority of the plants listed here have been studied thoroughly for their biological activity, their active component(s) or the active principle(s) are not yet fully understood. Examples of isolated and identified uterotonic plant compounds include diterpenes (kaurenoic acid, grandifloric acid and kauradienoic acid; isolated from *Montana tomentosa* and *Aspilia mossambicen*sis) [108–110], phenylpropanoid glucosides (Z-venusol; *Gunniera perpensa*), [111], heterocyclic aldehydes and fatty acids (5-hydroxymethylfurfural and linoleic acid; *Clivia miniata*), [75, 77], steroidal saponins (penogenin glucosides; *Paris polyphylla*) [112], plant sterols (β-sitosterol; *Punica granatum*) [113] (Fig. 3), and circular polypeptides, so-called cyclotides.

The discovery of the first cyclotide, kalata B1, from the coffee family (Rubiaceae) species *Oldenlandia affinis* was due to its use in African traditional medicine to accelerate childbirth by uterine stimulation [114, 115]. Cyclotides are disulfide-rich plant peptides [116] of about 30 amino acids in size and possess the unique structural features of a head-to-tail cyclised backbone and a knotted arrangement of three-disulfide bonds, referred to as a cyclic cystine knot (CKK) motif [116] (Fig. 4). The compact CKK motif makes cyclotides exceptionally resistant to thermal, chemical or enzymatic degradation [117]. In contrast to secondary plant metabolites, cyclotides are true gene products. Their biosynthesis starts from larger precursor proteins and reportedly involves enzymatic processing [118, 119] as well as protein folding events [120].

Lorentz Gran studied the pharmacological properties of kalata B1 and found that the peptide induced OT-like uterine muscle contractions in vitro with isolated rat and rabbit uteri and human uterine strips at concentrations of 10–20 µg/mL [115] and this has been confirmed by Gran and colleagues, which reported the uterotropic activity of kalata B1, B2 and B7 at concentrations of 0.5–20 µg/mL [121]. Similar effects were observed in vivo (rat and rabbit) upon peritoneal administration of ~ 20 µg/kg kalata B1 solution. However, intravenous injections of doses of ~ 1 mg/kg were found to be toxic (increased blood pressure and ventricular tachycardia) and eventually lethal (ventricular fibrillation) [115]. It is intriguing to further explore the uterotropic effect of cyclotides in molecular detail, in particular because kalata B1 [122], and other cyclotides (for instance tricyclos A and B from the violet plant *Viola tricolor* L. [123]), contain sequence and/or structural motifs that are similar to the presumed activity-bearing motifs in the OT peptide [124, 125]. Aside from their uterotropic activity, cyclotides also exhibit a range of other biological functions, including haemolytic [126], anti-neurotensin [127], anti-HIV [128] cytotoxic [129], anti-bacterial [130], anti-fouling [131] and nematocidal [132]. One of their main natural roles...
Table 1 Uterotonic plants and their active compounds.

<table>
<thead>
<tr>
<th>Plant (scientific name; family, order)</th>
<th>Part of plant, extract</th>
<th>Active compound(s)</th>
<th>Uterotonic principle (mode-of-action)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenia globosa Engl. (Passifloraceae, Malpighiales)</td>
<td>Tuber, hot water extract</td>
<td>–</td>
<td>Dose-dependent contraction of the rat uterus; traditional use: hastening parturition in domestic animals</td>
<td>[163]</td>
</tr>
<tr>
<td>Agapanthus africanaus (L.) Hoffmg. (Amaryllidaceae, Asparagales)</td>
<td>Leaf, aqueous extract</td>
<td>–</td>
<td>Causes uterine smooth muscle contractions (uterotonic); agonist activity on uterine muscarinic receptors (Ca²⁺-channels) and promotion of prostaglandin synthesis</td>
<td>[164]</td>
</tr>
<tr>
<td>Asclepias fructicosa</td>
<td>Wood, aqueous extract</td>
<td>–</td>
<td>Stimulation of uterine muscle contraction</td>
<td>[76]</td>
</tr>
<tr>
<td>Aegipila mossambicensis (Oliv.) Wild (Asteraceae, Asterales)</td>
<td>Leaf, methanol extract</td>
<td>Kaurenoic and grandifloronic acid (diterpenes)²</td>
<td>Potent uterotonic activity; fertility regulator in female chimpanzees</td>
<td>[165]</td>
</tr>
<tr>
<td>Bambuseae sp. Kunth ex Dumont. (Poaceae, Poales)</td>
<td>Green bamboo shoots, aqueous extract</td>
<td>Serotonin-like compounds</td>
<td>Induction of uterine contractions; serotonin antagonist blocked the effect; carboxypeptidase and boiling did not affect activity</td>
<td>[166]</td>
</tr>
<tr>
<td>Bidens pilosa L. (Asteraceae, Asterales)</td>
<td>Leaf, aqueous/methanolic extract</td>
<td>–</td>
<td>Increase of uterine motility; strongly augments oxytocin activity; weak uterine stimulating activity</td>
<td>[150, 167]</td>
</tr>
<tr>
<td>Bridelia atroviridis</td>
<td>Leaf, aqueous extract</td>
<td>–</td>
<td>Induction of uterine contraction (rat) by calcium mobilisation from intra- and extracellular compartments and activation of phospholipase C via G-protein activation</td>
<td>[168]</td>
</tr>
<tr>
<td>Byrsonarcus coccineus Schum. &amp; Thorn. (Connaraceae, Oxalidales)</td>
<td>Leaf, ethanol extract</td>
<td>Carbohydrates, tannins, flavonoids, balsams</td>
<td>Repeated treatment with extract enhanced spontaneous uterine muscle contractions; possibly involvement of β-adrenergic receptors</td>
<td>[169]</td>
</tr>
<tr>
<td>Carica papaya L. (Caricaceae, Brassicales)</td>
<td>Crude papaya latex</td>
<td>–</td>
<td>Induction of spasmodic (tetanic spasms) contraction of uterus muscle, similar to oxytocin and prostaglandin F₂α</td>
<td>[170]</td>
</tr>
<tr>
<td>Citrus hystrix DC. (Rutaceae, Sapindales)</td>
<td>Fruit peel, alcohol and chloroform extract</td>
<td>Menthol-related compounds</td>
<td>Stimulation of uterine contractions; increased frequency of contraction; antifertility activity, increase in uterine weight (when administered simultaneously with oestrogen)</td>
<td>[171]</td>
</tr>
<tr>
<td>Clivia miniata (Lindl.) Regel (Amaryllidaceae, Asparagales)</td>
<td>Leaf and root, aqueous extract (boiled preparation)</td>
<td>5-hydroxymethyl-2-furan-carbox aldehyde (heterocyclic aldehyde); linoleic acid (fatty acid)</td>
<td>Uterotonic activity; extracts do not affect the max. response of oxytocin- or acetylcholine-induced contractions; increased frequency of spontaneous contractions; stimulation of uterine contractions by activation of cholinergic and prostaglandin association</td>
<td>[75, 77, 164]</td>
</tr>
<tr>
<td>Ekebergia capensis Sparrm. (Meliaceae, Sapindales)</td>
<td>Wood, aqueous extract</td>
<td>–</td>
<td>Total extract induced uterine muscle tension followed by rhythmic activity of increasing amplitude; fraction produced stimulating action of uterus followed by an increase in the frequency of contractions</td>
<td>[76]</td>
</tr>
<tr>
<td>Elephorbia drupifera (Thomn.) Stapf (Euphorbiaceae, Malpighiales)</td>
<td>Leaf, hot water extract</td>
<td>–</td>
<td>Extract induced uterine contractions (rat), possibly due to release of acetylcholine and stimulation of muscarinic receptors</td>
<td>[172]</td>
</tr>
<tr>
<td>Erythroxylum coca Lam. (Erythroxylaceae, Malpighiales)</td>
<td>Pure substance</td>
<td>Cocaine (alkaloid)</td>
<td>Cocaine acutely increases contractile activity in myometrium isolated from pregnant women; it augments spontaneous contractility and the response to adrenergic and non-adrenergic contractile agonists</td>
<td>[173]</td>
</tr>
<tr>
<td>Exocaricia cochininchinensis Lour.² (Euphorbiaceae, Malpighiales)</td>
<td>Latex of leaves, acetone extract, ethyl acetate fraction</td>
<td>Daphnane, tiglane (diterpene esters)</td>
<td>Uterotonic activity</td>
<td>[174]</td>
</tr>
<tr>
<td>Ficus exasperata Vahl (Moraceae, Rosales)</td>
<td>Leaf, aqueous extracts</td>
<td>–</td>
<td>Stimulation of uterine contractility; possibly due to activation of histamine H1- and/or α-adrenergic receptors; interference with Ca²⁺-channels and/or stimulation of prostaglandin synthesis</td>
<td>[175]</td>
</tr>
<tr>
<td>Globimetula brownii (Engler) Van Tieghem (Loranthaceae, Santalales)</td>
<td>Leaf, aqueous extract</td>
<td>–</td>
<td>Uterotonic affect in rat uterus, probably by agonising muscarinic receptors</td>
<td>[176]</td>
</tr>
<tr>
<td>Grewia occidentalis L. (Grewioidaeae, Malvaceae)</td>
<td>Wood, aqueous extract</td>
<td>–</td>
<td>Total extract produced tonic uterine muscle rhythm of extremely low amplitude and low response (tonic compounds); fraction produced well synchronised response of regular and rhythmic contractions</td>
<td>[76]</td>
</tr>
<tr>
<td>Gunnera perennis L. (Gunneraceae, Gunnerales)</td>
<td>Dry rhizomes, aqueous extracts (boiled preparation)</td>
<td>Zvenusol (phenyl-propenoid glucoside); pyrogalol, sucinnic acid, lactic acid, and trimethyl ether of ellagic acid glucoside</td>
<td>Extract directly stimulates a contractile response of the uterine muscle; upon removal of extract the tissue enters a state of continuous spontaneous contractility; muscarinic receptor system may be involved in the direct contractile response to the whole plant extract; pure venusol did not elicited a direct response but a state of spontaneous contractility</td>
<td>[111, 177]</td>
</tr>
</tbody>
</table>

continued next page
### Table 1 Uterotonic plants and their active compounds. (continued)

<table>
<thead>
<tr>
<th>Plant (scientific name; family, order)</th>
<th>Part of plant, extract</th>
<th>Active compound(s)</th>
<th>Uterotonic principle (mode-of-action)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Harpagophytum procumbens</strong> (DC) (Pedaliaceae, Lamiales)</td>
<td>Secondary root, aqueous extract</td>
<td>^{−1}</td>
<td>Induced dose-dependent and significant contractions of pregnant and non-pregnant uterine strips (rats)</td>
<td>[178]</td>
</tr>
<tr>
<td><strong>Heterorhoea trifoliata</strong> (H. L. Wendl.) Eckl. &amp; Zeyh. (Apocynaceae, Apiales)</td>
<td>Root bark, aqueous extract</td>
<td>^{−1}</td>
<td>Uterus contractions (rat), mechanisms of contraction may involve stimulation of serotonin H1 receptors; more than one active ingredient</td>
<td>[179]</td>
</tr>
<tr>
<td><strong>Huntea umbellata</strong> K. Schum. (Apocephaceae, Gentianales)</td>
<td>Fruit pulp, aqueous extract</td>
<td>^{−1}</td>
<td>Significant, dose-dependant effect on rat uterus contractility; effect was blocked by atropine; potentiated the response of oxytocin; active principle: muscarinic cholinergic receptors</td>
<td>[149]</td>
</tr>
<tr>
<td><strong>Iboza riparia</strong> (Hochst.) N. E. Br. (Lamiaceae, Lamiales)</td>
<td>Whole plants, water/methanol extract</td>
<td>^{−1}</td>
<td>Weak activity on uterus stimulation (guinea pig)</td>
<td>[153], [167]</td>
</tr>
<tr>
<td><strong>Leonurus artemisia</strong> (L.) M. Roem (Apioaceae, Apiales)</td>
<td>Leaf, acidic methanol extract</td>
<td>Leonurine (alkaloid)</td>
<td>Stimulation of contractions in uterine smooth muscle; stimulating effect may attribute to the restoration of uterus to its normal size after birth</td>
<td>[180], [181]</td>
</tr>
<tr>
<td><strong>Luffa cylindrica</strong> (L.) M. Roem (Cucurbitaceae, Cucurbitales)</td>
<td>Leaf, aqueous extract</td>
<td>^{−1}</td>
<td>Causes strong (oxytocic) uterine contractions, immediate and stable &gt; 30 min; speed-up labour during childbirth; rupturing of uterine membranes</td>
<td>[150]</td>
</tr>
<tr>
<td><strong>Momordica foetida</strong> H. L. Wendl. (Acanthaceae, Lamiales)</td>
<td>Dry seeds, aqueous extract</td>
<td>Potent uterus contractile properties (rats), direct or indirect intervention of Ca^{2+}-ions or Ca^{2+}-channels</td>
<td>[151]</td>
<td></td>
</tr>
<tr>
<td><strong>Momordica foetida</strong> H. L. Wendl. (Acanthaceae, Lamiales)</td>
<td>Leaf, hot methanol extract</td>
<td>Amino acid/peptide</td>
<td>Potent oxytocin-like activity on uterine smooth muscles</td>
<td>[147]</td>
</tr>
<tr>
<td><strong>Montana tomentosa Cerv. (Asteraceae, Asterales)ATTRIB1</strong></td>
<td>Leaf, boiled aqueous extracts; hexane fractions</td>
<td>Kaurenoic acid, grandifloric acid, kaudaric acid (kauranes)</td>
<td>Contrary reports in the literature: Inhibition of spontaneous uterine contractions elicited by oxytocin, serotonin or acetylcholine (assayed in rat); uterotonic activity, i.e., increased tension and frequency of contraction (guinea pig, dog, cat, rabbit)</td>
<td>[108–110]</td>
</tr>
<tr>
<td><strong>Musongo cecropoides R. Brown</strong> (Urticaceae, Rosales)</td>
<td>Stem bark, aqueous extract</td>
<td>^{−1}</td>
<td>Dose-dependent increase in the force of uterine contractions; potentiation of uterine contractions induced by agonists; possibly by stimulation of muscarinic receptors of the uterus</td>
<td>[182]</td>
</tr>
<tr>
<td><strong>Newbouldia brevis</strong> (P. Beauv.) Seem. ex Bureau (Bignoniaceae, Lamiales)</td>
<td>Leaf, aqueous and ethanolic extracts</td>
<td>^{−1}</td>
<td>Increased frequency of spontaneous uterine contractions without affecting the amplitude; directly stimulates uterine contractility, possibly by influencing the open state of voltage dependent Ca^{2+}-channels</td>
<td>[183]</td>
</tr>
<tr>
<td><strong>Oldlandia affinis</strong> (R&amp;B) DC (Rubiaeaceae, Gentianales)</td>
<td>Whole plant, aqueous extract (boiled preparation)</td>
<td>Kalata B1, B2 and B7; circular polypeptides (cyclotides)</td>
<td>Contrary reports in the literature: Inhibition of spontaneous uterine contractions elicited by oxytocin, serotonin or acetylcholine (assayed in rat); uterotonic activity, i.e., increased tension and frequency of contraction (guinea pig, dog, cat, rabbit)</td>
<td>[115], [121]</td>
</tr>
<tr>
<td><strong>Paris polyphylla</strong> Sm. var. yunnanensis (Franch.) Hand.-Mazz. (Melanthiaceae, Liliaceae)</td>
<td>Rhizome, hot ethanol extract; bioassay-guided fractionation</td>
<td>Steroidal saponins, spirostanol glycosides</td>
<td>Dose-dependant induction of phasic myometrial contractions (rats); phospholipase C activation and [Ca^{2+}]i increase</td>
<td>[112]</td>
</tr>
<tr>
<td><strong>Parqueophia nigrescens</strong> (Afz.) Bullock (Apocephaceae, Gentianales)</td>
<td>Leaf, hydro-methanolic extract</td>
<td>^{−1}</td>
<td>Increasing amplitude of spontaneous contractions and slight elevation of muscular tonus (rat); calcium-dependent</td>
<td>[184]</td>
</tr>
<tr>
<td><strong>Pettenia alliacea</strong> L. (Phytolaccaceae, Caryophyllales)</td>
<td>Seeds, methanolic extract</td>
<td>^{−1}</td>
<td>Causes contractions of uterus; increased frequency and force of contraction on the contractile response to oxytocin; could influence progstaglandin (E_{2}, F_{2α}) synthesis</td>
<td>[185]</td>
</tr>
<tr>
<td><strong>Piper guineense</strong> L. (Piperaceae, Piperales)</td>
<td>Leaf and seeds, aqueous extract (boiled preparation)</td>
<td>Alkaloids, glycosides, flavonoids, phenols, phellobatins, tannins, saponins, antranoids, antiarquinoine</td>
<td>Enhances spontaneous uterine muscle contractions and short-term treatment enhanced maximum contractile response induced by oxytocin</td>
<td>[186]</td>
</tr>
<tr>
<td><strong>Prorocentrum lima</strong> (Ehrenberg) Stein (Dinophyta, Proorocentraeae, Proorocentraeae)</td>
<td>Pure substance, isolated from marine dinoflagellate</td>
<td>Okadaic acid</td>
<td>Uterotonic contraction (rat), not mediated through activation of membrane receptors or neurotransmitter release; no Ca^{2+}-entry through dihydropyridine-sensitive Ca^{2+}-channels</td>
<td>[187]</td>
</tr>
<tr>
<td><strong>Punic a granatum</strong> L. (Punicaeae, Myrtales)</td>
<td>“Pomegranate” seed, methanolic extract</td>
<td>β-sitosterol</td>
<td>Potent stimulator of phasic activity in rat uterus; due to non-ostrogenic effects of β-sitosterol as inhibitor of K’-channels and SERCA; [Ca^{2+}]i increase via L-type Ca^{2+}-channels and myosin light chain kinase activation</td>
<td>[113]</td>
</tr>
<tr>
<td><strong>Rhoeicosus tridentatus</strong> L. F. Wild &amp; R. B. Drumm. (Vitaceae, Vitales)</td>
<td>Roots and lignotubers, aqueous extract (boiled preparation)</td>
<td>^{−1}</td>
<td>Stimulates contractions of isolated rat uterus directly; contractile response is mediated predominantly by the muscarinic receptor system and the production of cycloxygenase metabolites</td>
<td>[188]</td>
</tr>
</tbody>
</table>

*continued next page*
therefore appears to be as plant defence molecules based on their insecticidal properties [133,134]; however, additional roles may yet be identified. Recent studies on the evolution, distribution and abundance of cyclotides in plants has led to the conclusion that there are at least 9000 novel cyclotides to be discovered in the violet family (Violaceae) [135] and an even greater number (up to 50000) in the coffee family (Rubiacaeae) [136]. The discovery of cyclotides and cyclotide-like proteins in other monocotyledon [137] and dicotyledon plant families suggests that cyclotides are much more numerous than originally anticipated. The family of cyclotides impresses not only by their sheer number, but also by their diversity. Typically one species can express 15–60 different, unique cyclotides [136,138] and a recent report suggests this number may be increased by varying growth conditions [139]. Their diversity is a result of the conserved cysteine framework and the backbone chains (loops) between those cysteines (Fig. 4), which are tolerant to various amino acid combinations. The plasticity and stability of the cyclotide framework and its tolerance to substitution [140] have been recently used as a tool for the development of novel pharmaceutical agents [141,142] and these examples underpin the application of cyclotides as combinatorial peptide scaffolds in pharmaceutical drug design. It has been suggested that cyclotides have evolved independently in various plant families [136]. It may be too early to provide a reliable, evidence-based evolutionary mechanism of cyclotides in flowering plants since “only” ~ 500 different species (~0.2% of total) from a total of > 250000 existing flowering plant species have been analysed to date [143]. Hence, it has to be clear that many more plant species need to be tested before it will be possible to make reliable conclusions on the origin and evolution of cyclotides within the plant kingdom. However, it is likely that cyclotides will ultimately comprise one of the largest protein families within the plant kingdom [136] and hence constitute an immense library of natural peptides, which may also be tested in the future for uterotonic activities. A starting point for future cyclotide discovery efforts would be plant families and orders that are in close phylogenetic proximity to the already positively identified ones, e.g., Celestrales, Oxalidales, Fabales, Rosales, Lamiales and Solanales (Fig. 4), and considering the number of species in each of these orders, there is great potential for future cyclotide discoveries.

### Conclusion and Outlook

The quest for novel uterotonics, cyclotide-producing plants Cyclotides are interesting targets for pharmaceutical and agrochemical applications due to their unique structural framework, range of bioactivities and sequence diversity [144–146] and based on their predicted number, which makes them one of the largest protein families within the plant kingdom, they constitute an immense library of natural peptides, which is accessible for drug discovery efforts [124]. Only recently have we started to comprehend the diversity and distribution of cyclotides and it seems likely that many more circular plant peptides await discovery and analysis. In the search for novel cyclotide-containing species one can apply the “taxonomy-guided” discovery approach (as discussed above), i.e., the analysis of novel cyclotide-related plants on a species and family level, and the “activity-guided” discovery approach by processing ethnobotanical and ethnopharmacological information followed by plant analysis. A closer look at other uterotonics plant species (Table 1) reveals starting points for further cyclotide discovery efforts. For example, the oxytocic activity from Monnemcha ciliatum [147] and Spandias mombin [148] is thought to be derived (at least in part) from amino acids and/or peptides, however, the exact nature of the active components is not yet known. Other uterotonics, plants, of which the active constituents are not yet elucidated, belong to the same families of already known cyclotide- or cyclotide-like containing plant families, namely Asclepias fruticosa [76], Hunteria umbellata (both Apocynaceae) [149], Luffa cylindrica [150], Momordica foetida [151] and Trichosanthes kirilowii [152] (all Cucurbitaceae). Furthermore, there are plants that have been traditionally used during pregnancy, childbirth

<table>
<thead>
<tr>
<th>Plant (scientific name; family, order)</th>
<th>Part of plant, extract</th>
<th>Active compound(s)</th>
<th>Uterotonic principle (mode-of-action)</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schisandra chinensis (Turcz.) Baill. (Schisandraceae, Austrobaileyales)</td>
<td>Tinctures of seeds and berries (ethanol)</td>
<td>–1</td>
<td>Uterus myotonctonic activity; stimulated the contraction of the uterus isolated from cats or rabbits</td>
<td>[189]</td>
</tr>
<tr>
<td>Solanum americanum L. (Solanaceae, Solanales)</td>
<td>Green fruit, aqueous extract</td>
<td>Saponins, glycol-alcohols</td>
<td>Stimulation of uterine contractions</td>
<td>[190]</td>
</tr>
<tr>
<td>Spondias mombin Lindl. (Anacardiaceae, Sapindales)</td>
<td>Leaf, methanol extract</td>
<td>Tannins, saponins, flavonoids, proteins, glycosides, resins, triterpenes, steroids</td>
<td>Oxytotic activity, may derive from Ca2+-ion mobilisation from the cytosol and direct musculotropic effects</td>
<td>[148]</td>
</tr>
<tr>
<td>Trichosanthes kirilowii Maxim. (Cucurbitaceae, Cucurbitales)</td>
<td>Root, extract</td>
<td>–1</td>
<td>Strengthened spontaneous contractions and enhanced response of uterus muscle to prostaglandin F2α and oxytocin</td>
<td>[152]</td>
</tr>
<tr>
<td>Vitex doniana Sweet (Lamiales, Vitaceae)</td>
<td>Bark, aqueous extract (boiled preparation)</td>
<td>Induced graded uterine contractions and potentiated the effects of prostaglandins, ergometrine and oxytocin; may act on voltage operated ion-channels and uterotonic receptors</td>
<td>[191]</td>
<td></td>
</tr>
</tbody>
</table>

1 Active compounds have not yet been identified. 2 These compounds are also found in Montanoa tomentosa. 3 Formerly known as Excoecaria bicolor Zoll. Ex. Hauck. 4 Pharmacological evidence not clear, since the extract also showed relaxing activity on skeletal and ileum smooth muscle. 5 Other species of the genus Luffa, e.g., L. echinata also show what has been reported to be uterotonic activity [192]. 6 L. cyclindrica contains ribosome-inactivating proteins, that are thought to be responsible for its abortifacient activity in mice [193]. 7 Active compound is possibly a small peptide with the sequence YLS. 8 Other species of the genus Montanoa spp. (i.e., M. frutescens, M. hibiscifolia) report uterotonic and spasmylic activities. 9 Other species from Violaceae and Rubiacaeae do contain cyclotides, potentially with uterotonic activity.
and gynaecological health-care, but have not yet been pharmacologically tested for uterotonc activity, such as Cephaelis tomentosa (Aubl.) Vahl. [97], Pentanisia prunelloides (Eckl.+Zeyh.) Walp. [98], Rondeletia stachyoides Donn. Smith [97], Sperrmacoe princeae (K. Schum.) Verdc. [153], Vangueria acupalica K. Schum. [153] (all Rubiaceae), Acokanthera abyssinica K. Schum. [96], Calotropis procera (Ait.) Dryand. [96] and Rauvolfia caffra Sonn. [98] (all Apocynaceae).

Both the taxonomy-guided and the activity-guided discovery approaches may lead to finding novel cyclotide-producing plant species, which will not only help to understand their diversity and evolution, but also provide novel molecules for biological testing and potentially new entities for drug development of uterotonics as well as tocolytic agents.

Importance of uterotonc active agents for clinical use
During pregnancy the uterus undergoes dramatic changes in its contractile activity, going from a state of quiescence to one of maximal contractile activity at labour. The initiation of labour is a complex physiological process that requires the expression and secretion of many maternal and foetal factors that exert their effect on the myometrium, the uterine smooth muscle responsible for expelling the foetus from the uterus in strong synchronous contractions. Abnormalities of this process have major clinical implications, including preterm labour, the single largest cause of maternal and perinatal mortality in developed countries and a major contributor to childhood developmental problems [154, 155]. An estimated 28% of the 4 million annual neonatal deaths are due to preterm birth and approximately 12.9 million babies are born prematurely every year, which estimates to a global prevalence of preterm birth of 9.6% [156, 157]. This results in huge costs to healthcare systems internationally. Figures from 2005 from the USA indicate that the annual societal economic cost (medical, educational, and lost productivity) associated with preterm birth from birth through early childhood was at least US$26.2 billion [158].

Currently used intervention therapies to suppress uterine contractions and delay labour, have harmful side effects for mother and baby. There is both a clinical need and a commercial opportunity for the identification of novel therapeutic agents for preterm labour. Current, so-called tocolytic therapies to inhibit preterm labour remain targeted at modulating uterine contractions. The only FDA approved treatment for preterm labour is ritodrine, a β2-adrenergic receptor agonist. However, it was withdrawn in 1999, due to side effects. A more widely used treatment for preterm labour, terbutaline, is not approved by the FDA for preterm labour. Other tocolytics include magnesium sulphate and nifedipine. The usefulness of β2-adrenergic agonists is limited by the side effects they produce, including cardiovascular side effects, such as heart palpitations (via stimulation of β1-adrenergic receptors). The side effects of PG synthesis inhibitors are well known and include ulcers, asthma and cardiovascular problems. Atofinity, an OT antagonist is available in Europe, but was denied regulatory approval in the USA. Thus, there is a need for treatments that are effective in reducing the premature birth rate and/or providing for longer gestation, with better safety and tolerability profiles. The ideal tocolytic agent would be highly specific for uterine smooth muscle and would have minimal side effects for both mother and neonate.

In contrast, induction of labour may be necessary in certain conditions and is advocated in cases of post-term pregnancy, lack of progress, oligohydramnios, suspected intrauterine growth restriction, maternal cardiac disease, pre-eclampsia/eclampsia, pre-labour rupture of membranes at term and foetal macrosomia [159]. Uterotonic or oxytocic drugs are used to induce or augment labour and in the prevention or treatment of post-partum bleeding [160]. OT is used for labour induction and associated complications during the third stage of labour include post-partum haemorrhage, retained placenta and uterine inversion [161]. Furthermore, PGs are used to induce labour and to prevent or treat post-partum haemorrhage [162], while synthetic ergot alkaloids cause strong titanic contraction of the uterus.

In summary, there is a great need for potent, selective and non-toxic therapeutic agents (agonists and antagonists) for recep-
tors/signalling pathways that regulate uterine muscle action. Traditionally used herbal medicines and their active ingredients, such as cyclotides found in flowering plants, are ideal starting points for biological target-oriented drug discovery efforts. The search for novel cyclotide-producing plants and their pharmacological characterisation may eventually lead to the development of novel uterotonic or tocolytic drugs.

Acknowledgements

The authors would like to thank C. Dobeš and B. Šarić-Kundalić for useful comments. Work on bioactive peptides and GPCR signalling in the laboratory of CWG is supported by the Austrian Science Fund (FWF; M1086 and P22889) and the European Union (Marie Curie, FP7, IRG no. 23097). Work on reproductive biology by MOŚ is supported by the Health Research Board of Ireland, the Higher Education Authority of Ireland’s Programme for Research in Third Level Institutions and the National University of Ireland, Galway, Ireland.

References

3 Csapo AI. Smooth muscle as a contractile unit. Physiol Rev Suppl 1962; 5: 7–33
4 Young RC. Myocytes, myometrium, and uterine contractions. Ann N Y Acad Sci 2007; 1101: 72–84
19 Ku CY, Qian A, Wen Y, Anwer K, Sanborn BM. Oxytocin stimulates myometrial guanosine triphosphatase and phospholipase-C activities via coupling to α1α1(1,1). Endocrinology 1995; 136: 1509–1515
20 Anker K, Hovinga JA, Sanborn BM. Antagonism of contractants and relaxants at the level of intracellular calcium and phosphoinositide turnover in the rat uterus. Endocrinology 1989; 124: 2995–3002
40 Grammatopoulos DK, Hillhouse EW. Role of corticotropin-releasing hormone in onset of labour. Lancet 1990; 339; 1546–1549
43 Grammatopoulos DK, Hillhouse EW. Activation of protein kinase C by oxytocin inhibits the biological activity of the human myometrial corticotropin-releasing hormone receptor at term. Endocrinology 1999; 140: 585–594

Gruber CW, O’Brien M. Uterotonic Plants and... Planta Med 2011; 77: 207–220

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


Ruzycki AL, Kulick A. Estrogen increases the expression of uterine protein kinase C isozymes in a tissue specific manner. Eur J Pharmacol 1996; 313: 257–263


Fry CH. Experimental models to study the physiology, pathophysiology, and pharmacology of the lower urinary tract. J Pharmacol Toxicol Methods 2004; 49: 201–210


Sevrum V, Raynor MW, Mulholland DA, Radooi DM. Supercritical fluid extraction and analysis of compounds from Clivia miniata for uterotonie activity. Planta Med 2001; 67: 451–455


Brower CH. Plants used for reproductive health in Oaxaca, Mexico. Econ Bot 1985; 39: 482–504

143 Gruber CW. Global cyclotide adventure: a journey dedicated to the discovery of circular peptides from flowering plants. Biopolymers, advance online publication 26 May 2010; DOI: 10.1002/bip.21414

144 Craik DJ. Seamless proteins tie up their loose ends. Science 2006; 311: 1563–1564


153 Bajore EO, Omogbai EKI, Ozolua RI. In vitro determination of the uterine stimulatory effect of the aqueous leaf extract of *Ficus exasperata*. J Ethnopharmacol 2010; 127: 502–507


158 Oluwole FS, Bolarinwa SA. The uterine contractile effect of *Petiveria alliacea* seeds. Fitoterapia 1998; 69: 3–6

159 Udob FU. Uterine muscle reactivity to repeated administration and phytochemistry of the leaf and seed extracts of *Piper guineense*. Phytother Res 1999; 13: 55–58


164 Ladeji O, Udob FU, Okeye ZSC. Activity of aqueous extract of the bark of *Vitex doniana* on uterine muscle response to drugs. Phytother Res 2005; 19: 804–806


166 Nath NB, Wong RNS, Yeung HW. 2 proteins with ribosome-inactivating, cytotoxic and abortifacient activities from seeds of *Luffa cylindrica* Roem (Cucurbitaceae). Biochem Int 1992; 27: 197–207


Gruber CW, O’Brien M. Uterotonic plants and... Planta Med 2011; 77: 207–220